Posting Date: August 12, 2021

Closing Date: August 22, 2021 11:30 a.m. ET

Reference Number: 21-053065

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – Program Specialist

At the National Cancer Institute (NCI), The Laboratory of Pathology (LP) is an integral component of the research and clinical community. Our goal is to be a globally recognized center of excellence in disease research, clinical diagnostics, and pathology education. The mission of the Laboratory of Pathology is to achieve the highest level of quality in research, diagnostics, and education. We support the research mission of the NCI by investigating the biology and genetics of cancer and other diseases, developing and applying leading edge technology to diagnostic pathology, providing collaborative support for clinical research protocols In this endeavor, we value scientific originality, integrity, and productivity while maintaining the highest level of ethical principles.

The National Cancer Institute plans to purchase Program Specialist from Courtney Newberry. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on August 22, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

We pursued several avenues of market research including a review of the current scientific literature, discussions with several colleagues in the field whose research involves similar systems, and evaluation of systems from previous experience while at the NIH. There was also significant input from the pathologist who will be using the microscope. We identified the best system to meet our clinical needs and within our current budget is the Olympus Microscope described herein.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request